# Gilead Sciences, Inc. (GILD) — Q4-2018 Earnings Results

**Report date:** 2019-02-04 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q4-2018

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.44 | N/A | -19.16% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about current market conditions impacting results. They remain focused on long-term growth strategies.

**Key quotes:**

> Management highlighted challenges in the market affecting performance.

> They emphasized a focus on long-term strategies despite short-term hurdles.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

The earnings report indicates that Gilead Sciences faced challenges in the fourth quarter, leading to a notable miss on EPS. The lack of revenue data and guidance may leave investors uncertain about the company's near-term prospects. The stock reaction is not available, but the defensive tone from management suggests caution moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q4-2018_